BMC
DNA icon

Bear Mountain Capital’s Ginkgo Bioworks DNA Stock Holding History

Bear Mountain Capital’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-125
Closed -$974 – 180
2024
Q3 		$974 Hold
125
– – ﹤0.01% 136
2024
Q2 		$1.44K Hold
125
– – ﹤0.01% 136
2024
Q1 		$4.36K Hold
125
– – ﹤0.01% 146
2023
Q4 		$6.1K Buy
+125
New +$7.65K ﹤0.01% 141

Other funds holding DNA

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bear Mountain Capital's DNA Position: Q4 2024 in Review

Bear Mountain Capital sold out of Ginkgo Bioworks (DNA) in Q4 2024, closing a stake of 125 shares — an estimated $974 sold.

Bear Mountain Capital first reported a position in DNA in Q4 2023 and held it in 4 quarters. The position peaked at $6.1K in Q4 2023. 166 funds tracked by Wall St. Rank hold DNA as of Q4 2024.

  • Bear Mountain Capital reported no remaining Ginkgo Bioworks position as of Q4 2024 after selling out during the quarter.
  • Bear Mountain Capital sold 125 Ginkgo Bioworks shares in Q4 2024, an estimated $974.
  • Bear Mountain Capital first reported a position in Ginkgo Bioworks in Q4 2023 and held it in 4 quarters.
  • Bear Mountain Capital's Ginkgo Bioworks position peaked at $6.1K in Q4 2023.
  • 166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2024.

Based on Bear Mountain Capital's 13F filing for Q4 2024, filed 3 Feb 2025.